Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 21:09:23 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Ultimovacs Q4 2022 - Closing in on top-line data

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Ultimovacs Q4 2022 - Closing in on top-line data

2023-02-17 07:10:00

Redeye comments on Ultimovacs’ Q4 2022 report, and we judge that INITIUM and NIPU top-line data in H1 2023e will constitute critical catalysts for the company. We believe that solid efficacy results in the coming readouts could provide essential data showing UV1's ability to enhance checkpoint inhibitors’ efficacy.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/